| 摘要 |
FIELD: medicine.SUBSTANCE: first concentration of the melanoma inhibitory activity (MIA) protein in a first biological sample taken from a mammalian patient prior to the treatment, and a second concentration of MIA in the second biological sample taken from the mammalian patient after the beginning of treatment. Then, the first and second concentrations of MIA are compared, and if the second concentration of MIA appears to be decreased as compared to the first concentration of MIA, a positive response to treatment manifested in downsizing the tumour is stated.EFFECT: invention allows the early assessment of the efficacy of the prescribed drugs and thereby provided well-timed correction of the therapy.7 cl, 10 dwg, 2 tbl, 4 ex |
